Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer

Breast Cancer Research and Treatment

Volumn 110, Issue 1, 2008, Pages 127-134

  Guarneri, Valentina ^a   Frassoldati, Antonio ^a   Ficarra, Guido ^a   Puglisi, Fabio ^b   Andreetta, Claudia ^b   Michelotti, Andrea ^c   Cresti, Nicola ^c   Boni, Corrado ^d   Bisagni, Giancarlo ^d   Berardi, Rossana ^e   Battelli, Nicola ^e   Santoro, Armando ^f   Banna, Giuseppe ^f   Bottini, Alberto ^g   Blasio, Beatrice Di ^h   Maiorana, Antonino ^a   Piacentini, Federico ^a   Giovannelli, Simona ^a   Jovic, Gordana ^a   Conte, PierFranco ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d Arcispedale Santa Maria Nuova   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g Oncology Division   (Italy)

^h UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Breast cancer; Chemotherapy; Gefitinib; MAPK; Primary systemic therapy

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; GEFITINIB; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; APOPTOSIS; ARTICLE; BLEEDING; BREAST CANCER; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NICK END LABELING; PHASE 1 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EPIRUBICIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; KI-67 ANTIGEN; NEOPLASM STAGING; PACLITAXEL; PATIENT COMPLIANCE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 44849083427     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9688-3     Document Type: Article

References (24)

1. Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor related peptides and their receptors in human malignancy. Crit Rev Haematol 19:183-232
2. Klijn JG, Berns PM, Schmitz PI et al (1992) The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13:3-17
3. Tang CK, Gong XQ, Moscatello DK et al (2000) Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 60:3081-3087
4. Khazaie K, Schirrmacher V, Lichtner RB (1993) EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 12:255-274
5. Messa C, Russo F, Caruso MG et al (1998) EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 37:285-289
6. Karunagaran D, Tzahar E, Beerli RR et al (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254-264
7. Wakeling AE, Guy SP, Woodburn JR et al (2002) ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749-5754
8. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158
9. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237-2246
10. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
11. Baselga J, Albanell J, Ruiz A et al (2005) Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23:5323-5333
12. Gasparini G, Sarmiento R, Amici S et al (2005) Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. Ann Oncol 16:1867-1873
13. Fountzilas G, Pectasides D, Kalogera-Fountzila A et al (2005) Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat 92:1-9
14. Ciardiello F, Troiani T, Caputo F et al (2006) Phase II study of gefitinib in combination with docetaxel as first line therapy in metastatic breast cancer. Br J cancer 94:1604-1609
15. Cobb MH (1999) MAP kinase pathway. Prog Biophys Mol Biol 71:479-500
16. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103:239-252
17. Ono K, Han J (2000) The p38 signal transduction pathway: activation and function. Cell Signal 12:1-13
18. Fan M, Chambers TC (2001) Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat 4:253-267
19. Shtil AA, Mandlekar S, Yu R et al (1999) Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene; 18:377-384
20. Huang Y, Sheikh MS, Fornace AJ et al (1999) Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells. Oncogene 18:3431-3439
21. Bacus SS, Gudkov AV, Lowe M et al (2001) Taxol-induced apoptosis depends on MAP kinase pathway (ERK and p38) and is independent of p53. Oncogene 20:147-155
22. Chan SK, Hill ME, Gullick WJ (2006) The role of the epidermal growth factor receptor in breast cancer. Mammary Gland Biol Neoplasia 11:3-11
23. Polychronis A, Dudley Sinnett H, Hadjiminas D et al (2005) Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6:383-391
24. Dowsett M, Smith I, Skene A et al (2006) Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR+ breast cancer. Proc Am Soc Clin Oncol 24:s6 (abstr 515)